![]() |
|
|
Vol. 54, Issue 1, 139-145, July 1998
Department of Pharmacology and Toxicology (C.T., E.M.-K., K.M.), Institute of Pharmacy, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany, and Department of Pharmaceutical Chemistry (M.H.B.C., U.H.), Institute of Pharmacy, University of Bonn, Kreuzbergweg 26, D-53115 Bonn, Germany
| |
Summary |
|---|
|
|
|---|
Muscarinic acetylcholine receptors bind allosteric modulators at a site
apart from the orthosteric site used by conventional ligands. We tested
in cardiac tissue whether modulator binding to ligand-occupied
muscarinic M2 receptors is a preferential event that can be
detected using a radioactive allosteric agent. The newly synthesized
dimethyl-W84
(N,N'-bis[3-(1,3-dihydro-1,3-dioxo-4-methyl-2H-isoindol-2-yl)propyl]-N,N,N',N'-tetramethyl-1,6-hexanediaminium diiodide) has a particular high potency at M2 receptors
occupied by the conventional antagonist
N-methylscopolamine (NMS); dissociation of
[3H]NMS is half-maximally retarded at an
EC50,diss value of 3 nM. Using obidoxime as an
"allosteric antagonist," evidence was found that dimethyl-W84
interacts with the postulated common allosteric site. Binding of
[3H]dimethyl-W84 (0.3 nM; specific activity,
168 Ci/mmol) was measured in porcine heart homogenates (4 mM Na2HPO4, 1 mM
KH2PO4, pH 7.4, 23°) in the presence of 1 µM NMS. Homologous competition experiments revealed two
components of saturable radioligand binding: one with a high affinity
(KD = 2 nM) and
small capacity (
30% of total saturable binding) and the other with
a 20,000-fold lower affinity. The Bmax value
of the high affinity sites (68 fmol/mg protein) matched muscarinic
receptor density as determined by [3H]NMS (79 fmol/mg).
Prototype allosteric agents, alcuronium, W84 (the parent compound of
the radioligand), and gallamine, displaced high affinity
[3H]dimethyl-W84 binding concentration-dependently
(pKi values = 8.62, 7.83, and 6.72, respectively). The binding affinities of the modulators were
in excellent correlation with their potencies to allosterically
stabilize NMS/receptor complexes (EC50,diss = 8.40, 7.72, and 6.74, respectively). We conclude that high affinity binding of
[3H]dimethyl-W84 reflects occupation of the common
allosteric site of M2 receptors.
| |
Introduction |
|---|
|
|
|---|
The
allosteric modulation of ligand-gated ion channels is a well known
phenomenon that is therapeutically used with the benzodiazepines at
-aminobutyric acidA receptors. However, also
in the comparably small G protein-coupled receptors, simultaneous
occupation by two different ligands of the transmitter binding site and
of a distinct allosteric site seems possible [e.g., in adenosine
A1 receptors (Bruns and Fergus, 1990
), dopamine
D2 receptors (Hoare and Strange, 1996
), and
2-adrenergic receptors (Wilson et
al., 1992
)]. Ternary complexes especially have been studied in
muscarinic acetylcholine receptors (Lee and El-Fakahany, 1991
; Lazareno
and Birdsall, 1995
; Tu
ek and Pro
ka, 1995
). As a
consequence of alloster binding to the muscarinic receptor protein, the
interaction between a ligand, such as the endogenous agonist
acetylcholine or the antagonist NMS, and the orthosteric site of the
receptor is altered. Ligand binding may be elevated, which opens the
perspective to develop enhancers of acetylcholine binding that
amplify cholinergic transmission at muscarinic synapses in a
subtype-specific fashion (Birdsall et al., 1997
;
Jakubík et al., 1997
). The event underlying an
elevation of ligand binding to muscarinic receptors on the molecular
level is a retardation of ligand dissociation that results from binding
of the allosteric agent to the ligand/receptor complex. Allosteric
agents also inhibit ligand association by an interaction with the free
receptor, yet phenomenologically, this action resembles the action of
competitive antagonists (Kostenis and Mohr, 1996
).
Until now, the binding characteristics of allosteric agents had to be derived from the effects they induced on ligand binding to the orthosteric site. Due to the lack of a radiolabeled allosteric agent, it has not been possible so far to investigate directly the binding of agents at the allosteric site. Furthermore, it has not been possible to reject by direct measurements the criticism that allosteric actions on ligand-occupied muscarinic receptors might be only an aspect of a rather nonspecific attachment to surface structures of cellular membranes, although there is ample evidence for a specific and preferential interaction.
The M2 receptor has been postulated to
contain a "common allosteric site" used by various structurally
heterogenous modulators (Ellis and Seidenberg, 1992
; Tränkle and
Mohr, 1997
). This site is thought to be located at the entrance of the
ligand binding pocket of the receptor protein (Tu
ek and
Pro
ka, 1995
; Tränkle et al., 1998
). Based on
previous structure-activity relationship studies (Holzgrabe et
al., 1996
; Holzgrabe and Hopfinger, 1996
), we intended to develop
a highly potent modulator of ligand binding at M2
receptors suitable to be applied in radioactive form for direct binding
measurements. The compound (Fig. 1) is a
dimethylated derivative of the alkane-bis-ammonium compound W84, which
previously has been discussed as a lead structure to develop new
allosteric agents (Tränkle et al., 1996
). In the first
part of our study, we characterized the allosteric effect of unlabeled
dimethyl-W84 on the binding of the orthosteric ligand
[3H]NMS in native M2
receptors applying porcine heart homogenates.
|
[3H]NMS was chosen because this radioligand has
been used previously to define the potency of various allosteric agents
to interact with NMS-liganded M2 receptors
(Tränkle et al., 1996
) and to check the common-site
hypothesis for the agents alcuronium, W84, and gallamine (Tränkle
and Mohr, 1997
), which were used here to test the specificity of
[3H]dimethyl-W84 binding. The experiments were
carried out in a buffer of low ionic strength devoid of divalent
cations to provide optimum conditions of a high affinity at the
allosteric site. In the second part of the study, the binding of
[3H]dimethyl-W84 was investigated under
identical conditions. In these experiments, we applied a high
concentration of NMS (1 µM) to occupy the orthosteric
site of the M2 receptors because of the following
reasons. First, as mentioned above, the ability to bind with rather
high affinity to ligand-occupied receptors distinguishes allosteric
modulators from conventional ligands. Second, the experiments with
[3H]NMS as the radioligand suggest that
dimethyl-W84 binds with slightly higher affinity to free receptors than
to [3H]NMS-liganded receptors. It cannot be
excluded that dimethyl-W84 in the free receptor might have a somewhat
different orientation compared with NMS-occupied receptors. Therefore,
a saturating concentration of NMS was applied to prevent this
possibility. Third, measurement of
[3H]dimethyl-W84 binding in NMS-occupied
receptors allowed a direct comparison with the functional experiments
in which the allosteric actions of nonlabeled dimethyl-W84 and other
modulators were characterized at
[3H]NMS-liganded receptors. Thus, it could be
checked whether the site of dimethyl-W84 binding is identical with the
site that mediates the actions of dimethyl-W84 and of the other applied
allosteric agents.
| |
Materials and Methods |
|---|
|
|
|---|
Synthesis of dimethyl-W84. Equimolar amounts of methylphthalic acid anhydride and 3-(N,N-dimethylamino)propylamine were refluxed in toluene using a water separator. After evaporation of the solvent, the product was purified by means of column chromatography (silica gel, MeOH/CH2Cl2 = 5:3) to give 85% of pure 6-methyl-N-[3-(N,N-dimethylamino)propyl]phthalimide. 1,6-Dibromohexane was alkylated with the phthalimide derivative by refluxing for 4 hr in acetonitrile. After evaporation of the acetonitrile, the remaining oil was washed several times with mixtures of ethanol/ethylacetate. Finally, the oil was dissolved in dichloromethane/ethanol, and the crystallization was initiated by the addition of diethylether to give 20% of pure dimethyl-W84.
Synthesis of the radioligand. N-(3-Bromopropyl)-4-methylphthalimide and 1,6-bis-(methylamino)hexane (ratio 2:1) were refluxed in acetonitrile for 5 hr to give 2,2'-[2,6-hexanediylbis[(methylimino)-3,1-propanediyl]]bis[4-methyl-1H-isoindole-1,3-(2H)-dione]. After column chromatographic purification (silica gel, MeOH/CH2Cl2 = 5:3), the bistertiary compound can be obtained in a yield of 20%. Methylation of both tertiary nitrogens can be achieved through treatment of the tertiary dimethyl-W84 with an excess of methyliodide in acetonitrile at room temperature (thin layer chromatography control silica gel, ethanol/concentrated NH3 = 4.5:1.5). The addition of diethyl ether to the reaction solution gives 85% of crystalline dimethyl-W84.
The NMR (1H and 13C) and IR data are in agreement with the structures; the elemental analyses are within ±0.4% of the theoretical values. The synthesis of the corresponding radiolabeled compound [3H]dimethyl-W84 was carried out at Amersham Life Science (Braunschweig, Germany), starting with the bistertiary compound and using the procedure described above. The radiochemical purity was 97%, and the specific activity was 168 Ci/mmol (6.22 TBq/mmol). The stock solution contains ethanol/water/methanol (84:15:1). In mixtures of ethanol and water, as well as in distilled water, no chemical decomposition of the unlabeled compound could be detected. In the buffer of the current study (4 mM Na2HPO4, 1 mM KH2PO4, pH 7.4, 23°), dimethyl-W84 undergoes slow hydrolysis with a half-life of 16 hr, which is manyfold beyond the applied incubation time.Membrane preparation.
Preparation of porcine heart
homogenates was carried out as described in detail previously
(Tränkle and Mohr, 1997
) at an ambient temperature of 3-6°. In
short, ventricular myocardium of freshly excised domestic pig hearts
obtained from the local slaughterhouse was cut into small pieces,
washed in sucrose solution (0.32 M), and homogenized using
a Waring blender and a Potter-Elvejhem homogenizer. The homogenate was
centrifuged for 11 min at 300 × g (2,000 rpm in a
Beckman rotor 35; Beckman Instruments, Columbia, MD). The resulting
supernatant was centrifuged for 41 min at 80,000 × g
(32,000 rpm in a Beckman rotor model 35). The homogenates intended for
use in a centrifugation assay (see below) instead of a filtration assay
were pelleted for 20 min at 20,900 × g (15,300 rpm in
a Beckman rotor model F241.5). Pellets were resuspended in a buffer
composed of 4 mM
Na2HPO4 and 1 mM KH2PO4, pH
7.4 (Na,K,Pi buffer). Aliquots of 1 ml were
frozen in liquid nitrogen and stored at
80°. Protein content
amounted to 4.7-8.5 mg/ml membrane suspension.
Binding assays. Cardiac membranes at a protein concentration of 300-700 µg/ml were incubated with the appropriate radioligand in the Na,K,Pi buffer at a temperature of 23°. Assays for homologous and heterologous competition measurements were carried out in volumes of 1.5 ml with an incubation time of 2 hr. For kinetic experiments, assays were prepared in larger volumes, and 1-ml aliquots were removed at appropriate intervals over a total period of 120 min.
Effects of dimethyl-W84 on [3H]NMS binding.
The binding characteristics of [3H]NMS (0.2 nM) under control conditions were investigated by
homologous competition experiments. Nonspecific
[3H]NMS binding was determined in the presence
of 1 µM atropine and did not exceed 5% of total binding
when membranes were separated by filtration; in centrifugation
experiments (see below), nonspecific [3H]NMS
binding was <10% of the total. In filtration experiments, the
log
equilibrium dissociation constant of [3H]NMS
binding amounted to a pKD value of
9.80 ± 0.11, and the density of binding sites to
Bmax was 100 ± 18 fmol/mg protein (mean ± standard error, three experiments); in centrifugation experiments, pKD was 9.56 ± 0.14, and Bmax was 79 ± 21 fmol/mg protein (mean ± standard error, six experiments). The effect of dimethyl-W84 on the equilibrium binding of
[3H]NMS (0.2 nM) was
determined in heterologous inhibition experiments with membrane
separation by filtration.
[3H]Dimethyl-W84 binding assay.
The
[3H]dimethyl-W84 experiments were carried out
in the presence of 1 µM NMS to occupy the orthosteric
binding site of the M2 receptor. NMS was allowed
to equilibrate for 5-10 min with the receptors before
[3H]dimethyl-W84 was added to the assay.
Alkane-bis-ammonium compounds closely related to dimethyl-W84 have been
reported to interact with acetylcholinesterase (Ohnesorge, 1969
); to
inhibit binding of [3H]dimethyl-W84 to
acetylcholinesterase, 1 µM physostigmine was added to the
incubation mixture. Control experiments revealed that at the indicated
concentrations, neither NMS nor physostigmine had an allosteric effect
on [3H]NMS dissociation and thus did not
interact with the allosteric site of the
[3H]NMS-occupied M2
receptor (data not shown). Membranes were separated by centrifugation
with 20,900 × g (15,300 rpm) in a Microfuge (Beckman)
for 20 min at 23°. After drawing off the supernatant, the tubes
containing the tightly packed pellet were carefully and quickly rinsed
with 1.5 ml of cold Na,K,Pi buffer to remove residual radioactivity from the tube wall. After resuspension of the
pellet in 1.5 ml of buffer, the suspension was transferred into a
scintillation vial filled with 10 ml of Ready Protein (Beckman) for
liquid scintillation counting.
Data analysis.
Data from individual experiments were
analyzed by computer-aided, nonlinear regression analysis using Prism
(ver. 2.01; GraphPAD Software, San Diego, CA). Analysis of homologous
competition data obtained with [3H]NMS was
based on the general Hill equation. Because the observed Hill
coefficients did not differ significantly from unity (partial F test, p > 0.05, data not shown),
IC50 values were determined from curve fits with
nH fixed to 1. The binding parameters
KD and
Bmax were calculated according to DeBlasi
et al. (1989)
. [3H]Dimethyl-W84
inhibition curves were fitted by applying an equation for a two-site
model. The binding parameters KD and
Bmax were derived from the high and low
affinity components of this fit according DeBlasi et al.
(1989)
. Ki values for the inhibitory action of the test compounds on
[3H]dimethyl-W84 binding were obtained from
IC50 values according to Cheng and Prusoff
(1973)
.
1.
[3H]NMS association was monophasic. The rate
constant of association was obtained by fitting a straight line to the
initial data points of specific [3H]NMS binding
(at 30 and 60 sec) as described, for instance, by Bennett and Yamamura
(1985)
1·min
1,
mean ± standard error, four experiments) and dissociation
k
1 (control, 0.165 ± 0.002 min
1, mean ± standard error, 16 experiments), respectively. Concentration-effect curves for the
diminution of the rate constants were obtained by curve fitting based
on a four-parameter logistic function.
The antagonistic action of obidoxime on the dimethyl-W84-induced
retardation of [3H]NMS dissociation was
analyzed according to Lazareno and Birdsall (1993)Drugs.
[3H]NMS was purchased from
DuPont-New England Nuclear (Bad Homburg, Germany). Alcuronium
dichloride was generously provided by Hoffmann-La Roche AG
(Grenzach-Wyhlen, Germany). Obidoxime chloride was a gift of Merck KG
(Darmstadt, Germany). Atropine sulfate, (
)-scopolamine
N-methylbromide, and gallamine triethiodide were from Sigma
Chemical (München, Germany). W84 was synthesized by Dr. Joachim
Pfeffer (University of Kiel, Kiel, Germany).
| |
Results |
|---|
|
|
|---|
Allosteric interaction of unlabeled dimethyl-W84 with
[3H]NMS binding.
Dimethyl-W84 allosterically
inhibits the dissociation of [3H]NMS from
porcine cardiac M2 receptors. The
concentration-effect curve is illustrated in Fig.
2 using the apparent rate constant of
[3H]NMS dissociation,
k
1, as a measure of the dissociation rate. The curve has a slope not different from unity (partial F test, p > 0.05) and levels off at
k
1 = 0, indicating that bound
dimethyl-W84 may completely prevent the dissociation of
[3H]NMS/receptor complexes. The concentration
of dimethyl-W84 causing a 50% decrease in the
k
1 of [3H]NMS
dissociation served as a measure of potency and amounted to
pEC50,diss = 8.51 ± 0.02 (mean ± standard error, eight experiments; Table
1). This value should reflect the
affinity of dimethyl-W84 at NMS-occupied M2
receptors (Lazareno and Birdsall, 1995
).
|
|
log equilibrium dissociation
constant for dimethyl-W84 binding to the free M2
receptor amounts to pKA = 8.32 ± 0.11, the cooperativity factor is
= 3.2 ± 0.12 (mean ± standard error, four experiments), and the equilibrium dissociation constant for dimethyl-W84 binding at the
[3H]NMS-occupied receptor is
log(
·KA) = 7.82. These values
are in acceptable correspondence with the respective binding constants as derived from the kinetic measurements. Thus, independent of the
experimental approach the affinity of dimethyl-W84 for the free
receptor can be predicted to be only slightly higher than the affinity
for the NMS-occupied receptor.
Interaction of dimethyl-W84 with the "allosteric antagonist" obidoxime. One aim was to check whether the action of dimethyl-W84 may be attributed to an interaction with the proposed common allosteric site of M2 receptors; therefore, we measured whether obidoxime is capable of antagonizing the allosteric action of dimethyl-W84 on [3H]NMS dissociation. A complete concentration-effect curve for dimethyl-W84 was determined in the presence of a high concentration of obidoxime; this curve was shifted to the right in a parallel fashion compared with the control curve (Fig. 3). The antagonistic effect of intermediate concentrations of obidoxime was studied using a single fixed concentration of 30 nM dimethyl-W84. The obidoxime-induced inhibition of the effect of dimethyl-W84 is compatible with a competitive interplay between obidoxime and dimethyl-W84. The pKB of obidoxime amounts to 4.71 ± 0.19 (mean ± standard error, two or three experiments).
|
Binding of [3H]dimethyl-W84 to NMS-occupied
receptors.
[3H]Dimethyl-W84, at a
concentration of 0.3 nM, was incubated with increasing
concentrations of unlabeled dimethyl-W84 in the presence of 1 µM NMS to occupy the orthosteric site. As shown in Fig.
4, binding of the radioligand was
diminished, indicating a saturable binding of
[3H]dimethyl-W84. The curve plateaus above
the zero level of [3H]dimethyl-W84 binding,
thus revealing a small component of nonsaturable radioligand binding.
The curve for inhibition of saturable
[3H]dimethyl-W84 binding was biphasic. The high
affinity component of [3H]dimethyl-W84 binding
is characterized by a capacity of 31% of the total saturable binding
and by an inflection point at pIC50,high = 8.61. As for a homologous competition curve, the equilibrium dissociation
constant for [3H]dimethyl-W84 binding to the
NMS-occupied receptors was calculated according to DeBlasi et
al. (1989)
as a
pKD,high value
of 8.74 ± 0.09 (mean ± standard error, seven experiments);
the binding site density was a Bmax value
of 68 ± 11 fmol/mg protein. The low affinity component has its
inflection point at a pIC50,low value of 4.43 corresponding to pKD,
low = 4.43 ± 0.08 (Bmax = 3.9 ± 0.8 nmol/mg protein). It was checked whether the high
affinity component of [3H]dimethyl-W84 vanished
in membranes pre-exposed to 80° for 15 min, under which condition the
specific binding of [3H]NMS was abolished. The
total binding of [3H]dimethyl-W84 was not
affected considerably, yet the shape of the inhibition curve changed.
Notably, as shown in Fig. 4 (inset), the heat-pretreated
membranes did not reveal a high affinity component of saturable
[3H]dimethyl-W84 binding. A low affinity
component of saturable [3H]dimethyl-W84 binding
was still present. The slope factor of the curve amounted to an
nH value of 0.48, which may indicate that the low affinity sites became heterogeneous on heat treatment. The
formation of sites with somewhat higher affinity may explain that total
[3H]dimethyl-W84 binding in the absence of
unlabeled dimethyl-W84 was not altered under heat treatment.
|
|
| |
Discussion |
|---|
|
|
|---|
Three features of the allosteric action of dimethyl-W84 were
pivotal for choosing this compound for radiolabeling. First, with a
half-maximally effective concentration for the inhibition of
[3H]NMS dissociation of an
EC50 value of 3 nM, dimethyl-W84 has a top position among various modulators in this respect. Previously, we
determined in a comparative study the potency of a wide spectrum of
compounds to interact allosterically with NMS-occupied receptors (Tränkle et al., 1996
). In that study, alcuronium was
found to be most potent with an EC50 value of 4 nM. We concluded that dimethyl-W84 should belong to the
compounds with highest affinity to NMS-occupied receptors. Second,
dimethyl-W84 is rather easily available by chemical synthesis compared
with alcuronium. Third, the results obtained with obidoxime as an
"allosteric antagonist" against dimethyl-W84
(pKb = 4.71) suggest that
dimethyl-W84 interacts with the postulated common allosteric site of
M2 receptors (Ellis and Seidenberg, 1992
);
recently, it was shown (Tränkle and Mohr, 1997
) that obidoxime
antagonized the effects of the allosteric model compounds gallamine,
W84, and alcuronium on [3H]NMS dissociation
with very similar potency (pKb = 4.70, 4.61, and 4.30, respectively). In line with the concept of a
common site are the findings of Pro
ka and Tu
ek (1995)
,
who could predict the effect of combinations of alcuronium and
gallamine on the equilibrium binding of [3H]NMS
in cardiac membranes by applying a model of a competitive interaction.
Lanzafame et al. (1997)
provided evidence for a competition among alcuronium, gallamine, and C7/3'-phth (the
heptane homologue of W84) in contracting guinea pig atria. Thus, under
various experimental conditions, the concept of a common allosteric
site on M2 receptors has been found to be
appropriate. The sensitivity of the allosteric action of dimethyl-W84
toward the "common-site antagonist" obidoxime was essential for the
decision to develop the tritiated compound as a potential common-site
radioligand.
In the [3H]dimethyl-W84 binding experiments, we
applied 1 µM NMS to occupy the orthosteric site of the
M2 receptor protein for the reasons mentioned
above. There is a negative cooperativity between dimethyl-W84 and NMS
(see Fig. 2), which, however, is rather weak. Nevertheless, the
question arises of whether high concentrations of dimethyl-W84 might
reduce occupation of the orthosteric site by NMS to a relevant extent.
In the absence of dimethyl-W84, 1 µM NMS
(pKD = 9.56) leads to a fractional
receptor occupancy of 0.9997. Dimethyl-W84 was applied in the
[3H]dimethyl-W84 binding experiments at a
maximum concentration of 10
3
M (see Fig. 3); from the characteristics of the
inhibition of [3H]NMS equilibrium binding by
dimethyl-W84 (see Fig. 2; pKD = 8.32,
= 3.2), it can be derived using the cooperativity model that the
fractional receptor occupancy by NMS in the presence of the highest
applied concentration of dimethyl-W84 (10
3
M) amounts to 0.9991. This implies that occupancy
of the orthosteric site by NMS is maintained even at high
concentrations of dimethyl-W84. Thus, for the analysis of the
[3H]dimethyl-W84 binding data, it seems
appropriate to consider the NMS/receptor complex as the binding site of
the allosteric agent.
The high affinity component of saturable [3H]dimethyl-W84 binding probably represents occupation of the allosteric site. This conclusion is derived from the following findings. The pKD, high value of 8.74 of high affinity binding of [3H]dimethyl-W84 to NMS-occupied receptors matches the pEC50,diss value of 8.51 for the allosteric effect of dimethyl-W84 on the dissociation of [3H]NMS/receptor complexes. The shape of the dimethyl-W84 allosteric effect curve (nH = 1.1, not significantly different from unity) corresponds with the shape of the [3H]dimethyl-W84 binding curve (nH = 1.0 by definition of the two-site model). Furthermore, the number of high affinity binding sites for [3H]dimethyl-W84 (Bmax = 68 ± 11 fmol/mg protein) is not significantly different from the number of [3H]NMS-binding sites (Bmax = 79 ± 21 fmol/mg protein), which supports the notion that high affinity [3H]dimethyl-W84 binding takes place at muscarinic receptors. Heat treatment, which abolishes specific binding of [3H]NMS, also eliminates the high affinity component of [3H]dimethyl-W84 binding. The other putative ligands for the allosteric site (i.e., alcuronium, W84, and gallamine) displace [3H]dimethyl-W84 binding at concentrations that match the concentrations for the allosteric effect of these agents on NMS dissociation. There is an excellent linear correlation between the pEC50,diss values and the binding constants pK of the four applied modulators, pEC50,diss = 0.87·pK + 0.90, r2 = 1.00. Thus, high affinity [3H]dimethyl-W84 binding apparently occurs at the site that mediates the allosteric effect of the modulators on NMS/receptor complexes.
The low affinity component of [3H]dimethyl-W84
binding probably represents nonspecific, yet saturable, binding of the
radioligand to the cardiac membranes. Because there is evidence that
modulators have fast binding kinetics at their site of action
(Tränkle and Mohr, 1997
), membranes were separated in the current
experiments by centrifugation instead of filtration. Thus, there was no
intensive washing of the membranes to reduce nonspecific radioligand
binding; it is common in filtration assays. The low affinity component has a very large capacity, suggesting that this binding is rather nonselective. The test compounds gallamine, alcuronium, and W84 inhibit
[3H]dimethyl-W84 binding in the low affinity
component, yet the binding affinity is low
(Ki =~100
µM) and hardly differs between the test
compounds. Using phosphatidylserine monolayers as an interphase model
and the displacement of
45Ca2+ as an indicator for
cationic drug binding (Girke et al., 1989
), we found that
dimethyl-W84, gallamine, alcuronium, and W84 bind with similar affinity
to this negatively charged phospholipid (Mieskes A, unpublished
observations). In 5 mM
Na,K,Pi buffer at 23°, as applied in the
current study, the half-maximally effective concentrations ranged
between 3 and 30 µM. Remarkably, the affinity of NMS to the phospholipid is ~1000-fold lower (Mieskes A,
unpublished observations). The comparably high propensity of
dimethyl-W84 to bind to a negatively charged interphase offers an
explanation of why the nonspecific binding of
[3H]dimethyl-W84 to the heart homogenate is
considerably higher than the nonspecific binding of
[3H]NMS.
Compared with the nonspecific binding, the specific binding of
[3H]dimethyl-W84 at the allosteric site of
M2 receptors has a ~20,000-fold higher affinity
(pKD, high = 8.74 versus pKD,
low = 4.43). This large difference in affinity demonstrates
that occupation of the allosteric site is a preferential event and not
an aspect of a nonspecific interaction with membrane interphases. This
finding will encourage to pursue in the development of allosteric
modulators as potential therapeutics. It may be assumed that this
preference does not vanish under physiological incubation conditions
because higher cation concentrations, including divalent cations, not only reduce the potency of allosteric modulators but also can diminish
the interaction of positively charged drugs with phospholipid interphases (Schlieper and Steiner, 1983
; Ohki, 1984
).
[3H]Dimethyl-W84 exemplifies that binding of
allosteric agents to the common site can be measured directly in
genuine M2 receptors of cardiac tissue. This
opens a new methodological perspective in the study of allosteric
phenomena. For instance, the effect on radioligand binding can be
investigated for drugs that have been supposed to interact with the
allosteric site such as the muscarinic agonist oxotremorine
(Jakubík et al., 1997
) and for allosteric agents
assumed not to attach to the common site (Tränkle and Mohr,
1997
).
Furthermore, the interaction of allosteric compounds with liganded and
with free M2 receptors may be compared as an
alternative approach to determine cooperativity factors. Preliminary
[3H]dimethyl-W84 experiments carried out in the
absence of unlabeled NMS gave a pKD
value of 8.89 ± 0.18 (mean ± standard error, four experiments) for radioalloster binding at free M2
receptors. This value matches the pEC50,ass value
of 8.81 for inhibition of [3H]NMS association
induced by dimethyl-W84 binding to free M2
receptors. The ratio between the KD
values of [3H]dimethyl-W84 binding to
NMS-occupied receptors (pKD = 8.74, KD = 1.82 nM)
and to free receptors (pKD = 8.89, KD = 1.26 nM), respectively, amounts to 1.4. This ratio favorably corresponds with the
shift factor of 1.5 between the curves (Fig. 2) for the effects of
dimethyl-W84 on the association of [3H]NMS and
on its dissociation (pEC50,diss = 8.51).
Furthermore, the [3H]dimethyl-W84 affinity
ratio is close to the cooperativity factor
value of 3.2 (Fig. 2) as
a measure derived from [3H]NMS equilibrium
experiments for the difference in affinity of dimethyl-W84 at free and
NMS-occupied receptors. Yet, for a detailed study of cooperativity
phenomena involving such small affinity shifts, it is desirable to
refine the binding assay in that nonspecific radioligand binding is
reduced, for instance, by changing the ionic composition of the assay
or by using cloned receptors at elevated concentrations.
In conclusion, a radiolabeled allosteric modulator of muscarinic receptors with high allosteric potency was developed. Evidence is presented for the first time that radioligand-binding measurements at the allosteric site of ligand-occupied muscarinic M2 receptors can be carried out. This finding opens a new methodological perspective in the study of allosteric interactions at muscarinic receptors.
| |
Acknowledgments |
|---|
We thank Iris Witten and Frauke Mörschel for their expert technical assistance. The active support of the project by Prof. Dr. K. H. Jakobs and Dr. A. Moritz (University of Essen, Essen, Germany) is gratefully indicated.
| |
Footnotes |
|---|
Received December 8, 1997; Accepted March 12, 1998
This work was supported by the Deutsche Forschungsgemeinschaft und the Fonds der Chemischen Industrie, Germany. H.M.B.C. acknowledges a grant given by the Katholischer Akademischer Austauschdienst.
Send reprint requests to: Klaus Mohr, Department of Pharmacology & Toxicology, Institute of Pharmacy, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany. E-mail: k.mohr{at}uni-bonn.de
| |
Abbreviations |
|---|
NMS, N-methylscopolamine; dimethyl-W84, N,N'-bis[3-(1,3-dihydro-1,3-dioxo-4-methyl-2H-isoindol-2-yl)propyl]-N,N,N',N'-tetramethyl-1,6-hexanediaminium diiodide .
| |
References |
|---|
|
|
|---|
ek S
(1997)
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
Mol Pharmacol
52:
172-179
ka J and
Tu
ek S
(1995)
Competition between positive and negative allosteric effectors on muscarinic receptors.
Mol Pharmacol
48:
696-702[Abstract].
ek S and
Pro
ka J
(1995)
Allosteric modulation of muscarinic acetylcholine receptors.
Trends Pharmacol Sci
16:
205-212[Medline].
2-adrenergic receptor but does not inhibit Na+/H+ exchange.
Mol Pharmacol
42:
175-179[Abstract].
This article has been cited by other articles:
![]() |
S. Prilla, J. Schrobang, J. Ellis, H.-D. Holtje, and K. Mohr Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity Mol. Pharmacol., July 1, 2006; 70(1): 181 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fruchart-Gaillard, G. Mourier, C. Marquer, A. Menez, and D. Servent Identification of Various Allosteric Interaction Sites on M1 Muscarinic Receptor Using 125I-Met35-Oxidized Muscarinic Toxin 7 Mol. Pharmacol., May 1, 2006; 69(5): 1641 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Trankle, A. Dittmann, U. Schulz, O. Weyand, S. Buller, K. Johren, E. Heller, N. J. M. Birdsall, U. Holzgrabe, J. Ellis, et al. Atypical Muscarinic Allosteric Modulation: Cooperativity between Modulators and Their Atypical Binding Topology in Muscarinic M2 and M2/M5 Chimeric Receptors Mol. Pharmacol., December 1, 2005; 68(6): 1597 - 1610. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. May, Y. Lin, P. M. Sexton, and A. Christopoulos Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 382 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Voigtlander, K. Johren, M. Mohr, A. Raasch, C. Trankle, S. Buller, J. Ellis, H.-D. Holtje, and K. Mohr Allosteric Site on Muscarinic Acetylcholine Receptors: Identification of Two Amino Acids in the Muscarinic M2 Receptor That Account Entirely for the M2/M5 Subtype Selectivities of Some Structurally Diverse Allosteric Ligands in N-Methylscopolamine-Occupied Receptors Mol. Pharmacol., July 1, 2003; 64(1): 21 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Trankle, O. Weyand, U. Voigtlander, A. Mynett, S. Lazareno, N. J. M. Birdsall, and K. Mohr Interactions of Orthosteric and Allosteric Ligands with [3H]Dimethyl-W84 at the Common Allosteric Site of Muscarinic M2 Receptors Mol. Pharmacol., July 1, 2003; 64(1): 180 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Buller, D. P. Zlotos, K. Mohr, and J. Ellis Allosteric Site on Muscarinic Acetylcholine Receptors: A Single Amino Acid in Transmembrane Region 7 Is Critical to the Subtype Selectivities of Caracurine V Derivatives and Alkane-Bisammonium Ligands Mol. Pharmacol., January 1, 2002; 61(1): 160 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-G. Gao, J. E. Van Muijlwijk-Koezen, A. Chen, C. E. Muller, A. P. Ijzerman, and K. A. Jacobson Allosteric Modulation of A3 Adenosine Receptors by a Series of 3-(2-Pyridinyl)isoquinoline Derivatives Mol. Pharmacol., November 1, 2001; 60(5): 1057 - 1063. [Abstract] [Full Text] |
||||
![]() |
C. Tränkle, O. Weyand, A. Schröter, and K. Mohr Using a Radioalloster to Test Predictions of the Cooperativity Model for Gallamine Binding to the Allosteric Site of Muscarinic Acetylcholine M2 Receptors Mol. Pharmacol., November 1, 1999; 56(5): 962 - 965. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||